Evotec OAI and Roche sign medicinal chemistry collaboration in oncology
Evotec OAI and Roche are expanding their partnership through a medicinal chemistry collaboration to identify and develop a clinical lead candidate for one of Roche's cancer targets.
Evotec OAI and Roche are expanding their partnership through a medicinal chemistry collaboration to identify and develop a clinical lead candidate for one of Roche's cancer targets.
The two companies have worked together on the production of chemical libraries since 2001, with Evotec OAI supplying chemical compound libraries to Roche for use in drug discovery screening programmes. This agreement expands the partnership into a co-operative lead optimisation programme.
'Our partnership with Roche in discovery chemistry has been highly successful, and was extended for a further two years in 2002. We are delighted that Roche has now also chosen us as their partner in the area of lead optimisation, which is a significant endorsement of our strategy of moving up the drug development value chain by integrating leading edge technologies to accelerate effective compound optimization,' said Joern Aldag, president and ceo of Evotec OAI.